CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Paroxetine +1 moredrug
Likely dose
Paroxetine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00560612
NCT00560612Phase 4Completed
CompareCT.gov

Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)

Durham VA Medical Center·interventional·Posted Nov 20, 2007·Updated Jun 18, 2019

In Brief

A Phase 4 clinical trial evaluating Paroxetine and Placebo for Stress Disorders, Post-Traumatic. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is: 1) To document the effectiveness and tolerability of paroxetine for the treatment of subthreshold posttraumatic stress disorder (PTSD) in veterans in the early post-deployment period; and 2) To determine the potential efficacy of paroxetine in preventing the progression of anxiety symptoms to PTSD and other anxiety disorders, and improving overall veteran function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Disorders, Post-Traumatic
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 20, 2007
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.6 years ago

Interventions

Paroxetinedrug

Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.

Placebodrug

Placebo: same as paroxetine (active comparator)